Treatment of idiopathic inflammatory myopathies

Current Opinion in Neurology

Volumn 16, Issue 5, 2003, Pages 569-575

  Amato, Anthony A ^a   Griggs, Robert C ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

Dermatomyositis; Inclusion body myositis; Inflammatory myopathy; Myositis; Polymyositis; Treatment

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FOLINIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POTASSIUM; PREDNISONE; TACROLIMUS; TUMS; VITAMIN D;

ABSORPTIOMETRY; ALOPECIA; AMBLYOPIA; ANXIETY DISORDER; BONE MARROW SUPPRESSION; BONE NECROSIS; CATARACT; CLINICAL TRIAL; CONFUSION; COUGHING; DERMATOMYOSITIS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DYSGEUSIA; EXERCISE; FLUSHING; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEADACHE; HEART ARRHYTHMIA; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFECTION; INFERTILITY; INFLUENZA; INSOMNIA; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; LUNG FIBROSIS; MUSCLE ATROPHY; MYOCARDITIS; NAUSEA; NEOPLASM; NEPHROTOXICITY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHYSIOTHERAPY; POLYMYOSITIS; REVIEW; SIDE EFFECT; SINUSITIS; STOMATITIS; TERATOGENESIS; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT GAIN;

CONTROLLED CLINICAL TRIALS; DERMATOMYOSITIS; DOUBLE-BLIND METHOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 0142042344     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200310000-00002     Document Type: Review

References (59)

1. Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin 1997; 15:615-648.
2. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996; 40:581-586.
3. Dalakas MC. Polymyositis, dermatomyositis, and inclusion body myositis. N Engl J Med 1991; 325:1487-1498.
4. Dalakas MC. Progress in inflammatory myopathies: good but not good enough. J Neurol Neurosurg Psychiatry 2001; 70:569-573.
5. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705-713.
6. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis: observations in 40 patients. Brain 1989; 112:727-747.
7. Mastaglia FL, Garlep MJ, Philips BA, Zilco PJ. Inflammatory myopathies: clinical, diagnostic, and therapeutic aspects. Muscle Nerve 2003; 27:407-425. This invited review presents an up-to-date treatise on clinical features, pathogenic basis, and treatment of dermatomyositis, polymyositis and IBM.
8. Oddis CV. Idiopathic inflammatory myopathy: management and prognosis. Rheum Dis Clin North Am 2002; 28:979-1001. A rheumatologist's perspective on treatment of inflammatory myopathies.
9. Joffe MM, Love LA, Leff RL. Drug therapy of idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94:379-387.
10. Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 1993; 72:225-235.
11. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993-2000.
12. Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for polymyositis. Ann Intern Med 1980; 92:365-369.
13. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukopheresis in polymyositis and dermatomyositis. N Eng J Med 1992; 326:1380-1384.
14. Dalakas MC, Sonies B, Dambrosia JM, et al. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 8:712-716.
15. Walter MC, Lochmuller H, Toepferm, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000; 247:22-28.
16. Dalakas MC, Koffman B, Fuji M, et al. A controlled trial of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56:323-327.
17. Muscle Study Group. A randomized trial of βINF1a (Avonex) in patients with inclusion body myositis (IBM). Neurology 2001; 57:1566-1570.
18. Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58:1081-1087. This was a double-blind, placebo-controlled, cross-over study of oxandrolone for 3 months in 19 patients with IBM. A trend towards improvement was demonstrated in the maximum voluntary isometric contraction testing MVICT scores with oxandrolone and in the number of stairs climbed, but no significant differences were noted in other outcome measures.
19. Badsrising UA, Maat-Schieman MLC, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51:369-372. This was a 48-month randomized, placebo-controlled trial of methotrexate (up to 20 mg/week orally) in 44 patients with IBM. No treatment-associated improvement was seen.
20. Barohn RJ. The therapeutic dilemma of inclusion body myositis. Neurology 1997; 48:567-568.
21. Tymms KE, Webb J. Dermatomyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985; 12:1140-1148.
22. Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 1987; 30:328-334.
23. Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to therapy. Neurology 1995; 45:1302-1304.
24. Rose M, McDermott M, Thornton CA, et al. Prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 2001; 57:548-550.
25. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339:292-292.
26. Cagnoli M, Marchesoni A, Tosi S. Combined steroid, methotrexate, and chlorambucil therapy for steroid resistant dermatomyositis. Clin Exp Rheumatol 1991; 9:658-659.
27. Giannini M, Callen JP. Treatment of dermatomyositis with methotrexate and prednisone. Arch Dermatol 1979; 115:1251-1252.
28. Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81:182-189.
29. Bunch TW. Prednisone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum 1981; 24:45-48.
30. Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology 1986; 36:35-39.
31. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous globulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91:162-168.
32. Hanslik T, Jaccard A, Guillon JM, et al. Polymyositis and chronic graft-versus-host disease: efficacy of intravenous gammaglobulin. J Am Acad Dermatol 1993; 28:492-493.
33. Jann S, Beretta S, Moggio M, et al. High-dose intravenous immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry 1992; 55:60-62.
34. Lang BA, Laxer RM, Murphy G, et al. Treatment of dermatomyositis with intravenous immunoglobulin. Am J Med 1991; 91:169-172.
35. Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27:2498-2503.
36. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term follow up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002; 46:467-474. Thirty-five patients with refractory polymyositis were treated with IVIG 2 g/kg/ month for 4-6 months in an open-label fashion. Clinical improvement, lower creatine kinase levels, and prednisone dose reduction by 50% or more were seen in 25/35 patients.
37. Soueidan SA, Dalakas MC. Treatment of inclusion body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43:876-879.
38. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 44:1516-1518.
39. Leroy JP, Drosos AA, Yiannopoulos DI, et al. Intravenous pulse cyclophosphamide therapy in myositis and Sjögren's syndrome. Arthritis Rheum 1990; 33:1579-1581.
40. Cronin ME, Miller FW, Hicks JE, et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989; 16:1225-1228.
41. Fries JF, Sharp GC, McDevitt HO, et al. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis Rheum 1973; 16:154-162.
42. Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993; 36:319-324.
43. Wallace DJ, Metzger AL, White KK. Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis. Arthritis Rheum 1985; 28:590-592.
44. Adams EM, Pucino F, Yarboro C, et al. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of end-point measures. J Rheumatol 1999; 26:352-360.
45. Correia O, Polonia J, Nunes JP, et al. Severe acute form of adult dermatomyositis treated with cyclosporine. Int J Dermatol 1992; 31:517-519.
46. Heckmatt J, Hasson N, Saunders C, et al. Cyclosporine in juvenile dermatomyositis. Lancet 1989; 1:1063-1066.
47. Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporine A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000; 27:2855-2859.
48. Lueck CJ, Trend P, Swash M. Cyclosporine in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991; 54:1007-1008.
49. Mehregan AL, Su WPD. Cyclosporine treatment for dermatomyositis/ polymyositis. Cutis 1993; 51:59-61.
50. Pistoia V, Buoncompagni A, Scribanis R, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis- dermatomyositis: results of a preliminary study. Clin Exp Rheumatol 1993; 11:203-208.
51. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353:1211-1217.
52. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations: a series of four cases. J Rheumatol 2000; 27:1542-1545.
53. Schneider C, Gold R, Schafers M, Toyka KV. Mycophenolate mofetil in the therapy of refractory polymyositis. Muscle Nerve 2002; 25:286-288.
54. Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular disease. Neurology 2001; 56:94-96.
55. Hengstman G, Van Den Hoogen F, Van Den Engelen B, et al. Anti-TNF blockade with Infliximab in polymyositis and dermatomyositis. Arthritis Rheum 2000; 43 (Suppl 1):S193.
56. Maillard SM, Wilkinson NMR, Beresford MW, et al. The treatment of persistent severe idiopathic inflammatory myositis with anti-TNF therapy. Ann Rheum Dis 2002; 61 (Suppl 1):S143.
57. Miller ML, Mendez E, Klein-Gitelman MS, Pachman LM. Experience with etanercept in chronic juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum 2000; 43:1883.
58. Nzeusseau A, Durez P, Houssain FA, Devogelaer JP. Successful use of Infliximab in a case of refractory juvenile dermatomyositis. Arthritis Rheum 2001; 44:S90.
59. Saadeh CK. Etanercept is effective in the treatment of polymyositis/ dermatomyositis which is refractory to conventional therapy including corticosteroids and other disease modifying agents. Arthritis Rheum 2000; 43 (Suppl 1):S193